Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 9 studies | 34% ± 13% | |
hepatocyte | 4 studies | 45% ± 23% | |
hepatic stellate cell | 3 studies | 31% ± 10% |
Insufficient scRNA-seq data for expression of AGTR1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 3402.55 | 226 / 226 | 94% | 27.83 | 383 / 406 |
adrenal gland | 100% | 3712.09 | 258 / 258 | 69% | 15.11 | 159 / 230 |
breast | 100% | 4031.56 | 458 / 459 | 60% | 36.09 | 666 / 1118 |
prostate | 64% | 455.70 | 156 / 245 | 85% | 23.69 | 427 / 502 |
kidney | 87% | 851.03 | 77 / 89 | 51% | 8.98 | 463 / 901 |
thymus | 98% | 1573.34 | 637 / 653 | 25% | 1.57 | 150 / 605 |
lung | 97% | 1076.45 | 563 / 578 | 19% | 1.28 | 214 / 1155 |
bladder | 95% | 1428.33 | 20 / 21 | 13% | 0.99 | 63 / 504 |
adipose | 100% | 5398.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
skin | 81% | 1044.51 | 1468 / 1809 | 6% | 1.07 | 28 / 472 |
intestine | 76% | 1304.40 | 738 / 966 | 9% | 0.58 | 47 / 527 |
muscle | 84% | 654.21 | 672 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 81% | 853.52 | 1080 / 1335 | 0% | 0 | 0 / 0 |
spleen | 77% | 506.84 | 185 / 241 | 0% | 0 | 0 / 0 |
esophagus | 64% | 611.18 | 920 / 1445 | 8% | 0.43 | 15 / 183 |
uterus | 56% | 415.15 | 96 / 170 | 13% | 0.99 | 58 / 459 |
pancreas | 17% | 73.90 | 55 / 328 | 46% | 2.44 | 82 / 178 |
heart | 58% | 462.62 | 496 / 861 | 0% | 0 | 0 / 0 |
stomach | 40% | 521.45 | 144 / 359 | 14% | 0.84 | 41 / 286 |
ovary | 28% | 278.03 | 50 / 180 | 8% | 0.37 | 33 / 430 |
brain | 3% | 25.37 | 77 / 2642 | 5% | 0.27 | 37 / 705 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.05 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010744 | Biological process | positive regulation of macrophage derived foam cell differentiation |
GO_0060326 | Biological process | cell chemotaxis |
GO_0006954 | Biological process | inflammatory response |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0051247 | Biological process | positive regulation of protein metabolic process |
GO_0001558 | Biological process | regulation of cell growth |
GO_0019722 | Biological process | calcium-mediated signaling |
GO_0019229 | Biological process | regulation of vasoconstriction |
GO_0035813 | Biological process | regulation of renal sodium excretion |
GO_0003081 | Biological process | regulation of systemic arterial blood pressure by renin-angiotensin |
GO_0001822 | Biological process | kidney development |
GO_0002034 | Biological process | maintenance of blood vessel diameter homeostasis by renin-angiotensin |
GO_0086097 | Biological process | phospholipase C-activating angiotensin-activated signaling pathway |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_1905920 | Biological process | positive regulation of CoA-transferase activity |
GO_0097746 | Biological process | blood vessel diameter maintenance |
GO_0032430 | Biological process | positive regulation of phospholipase A2 activity |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0034374 | Biological process | low-density lipoprotein particle remodeling |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
GO_0038166 | Biological process | angiotensin-activated signaling pathway |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0002018 | Biological process | renin-angiotensin regulation of aldosterone production |
GO_0007266 | Biological process | Rho protein signal transduction |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_1903589 | Biological process | positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031711 | Molecular function | bradykinin receptor binding |
GO_0001596 | Molecular function | angiotensin type I receptor activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
GO_0004945 | Molecular function | angiotensin type II receptor activity |
Gene name | AGTR1 |
Protein name | Type-1 angiotensin II receptor Type-1 angiotensin II receptor (AT1AR) (AT1BR) (Angiotensin II type-1 receptor) (AT1 receptor) |
Synonyms | AT2R1 AT2R1B AGTR1A hCG_2022206 AGTR1B |
Description | FUNCTION: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney . The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C . .; FUNCTION: (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. . FUNCTION: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. . FUNCTION: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. . FUNCTION: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. . FUNCTION: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. . |
Accessions | Q53YY0 D3DNG8 P30556 ENST00000475347.5 ENST00000474935.5 ENST00000418473.7 ENST00000404754.2 ENST00000497524.5 A0A0A0MSE3 ENST00000402260 ENST00000349243.8 Q6NUP5 ENST00000402260.2 ENST00000418473 ENST00000461609.1 |